An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of SPM 927 in Subjects With Chronic Refractory Neuropathic Pain.

Trial Profile

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of SPM 927 in Subjects With Chronic Refractory Neuropathic Pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 07 Apr 2011 Status changed from active, no longer recruiting to completedas reported by ClinicalTrials.gov.
    • 11 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Planned end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top